Wells Fargo Downgrades enGene Therapeutics to Equal-Weight, Lowers Price Target to $2

Benzinga Newsdesk www.benzinga.com Negative 90.7%

Neg 90.7% Neu 0% Pos 0%

Wells Fargo analyst Yanan Zhu downgrades enGene Therapeutics (NASDAQ:ENGN) from Overweight to Equal-Weight and lowers the price target from $25 to $2.